Figure 4.

The effect of IP3R blocker and SERCA inhibitor on FDA-induced uterine contraction. Representative image of isometric uterine contraction following administration of (a) oxytocin plus 2-APB, (b) FDA 2 mg/ml plus 2-APB, (c) oxytocin plus thapsigargin and (d) FDA 2 mg/ml plus thapsigargin while bar chart shows the Emax following oxytocin and FDA administration with and without the presence of 2-APB and thapsigargin. No significant difference was noted following 2-APB administration in the FDA treated group while thapsigargin caused a slight but significant increase in the Emax.